Patents by Inventor John Dorrance
John Dorrance has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10925399Abstract: Modular organizer systems and components thereof are disclosed. In some embodiments, a first panel may include a plurality of elongate and parallel structural members and a plurality of bridges that are attached to, or formed with, a first portion of the plurality of structural members such that (a) a bridge spans between the first portions of each pair of adjacent structural members and (b) a cavity is defined between second portions of each pair of adjacent structural members. Bridge(s) may be sized to be received in a cavity of a second panel. The first panel may additionally include a projection assembly having a projection member and a projection bridge, which may be configured to be received in the second end structural member of a third panel. The second end structural member may include an opening configured to receive at least a portion of a projection assembly of a fourth panel.Type: GrantFiled: June 6, 2018Date of Patent: February 23, 2021Assignee: RDLL Investments LLCInventors: Raye Miles, Douglas Porter, John Dorrance, Kenneth Courian
-
Publication number: 20180344029Abstract: Modular organizer systems and components thereof are disclosed. In some embodiments, a first panel may include a plurality of elongate and parallel structural members and a plurality of bridges that are attached to, or formed with, a first portion of the plurality of structural members such that (a) a bridge spans between the first portions of each pair of adjacent structural members and (b) a cavity is defined between second portions of each pair of adjacent structural members. Bridge(s) may be sized to be received in a cavity of a second panel. The first panel may additionally include a projection assembly having a projection member and a projection bridge, which may be configured to be received in the second end structural member of a third panel. The second end structural member may include an opening configured to receive at least a portion of a projection assembly of a fourth panel.Type: ApplicationFiled: June 6, 2018Publication date: December 6, 2018Applicant: RDLL Investments LLCInventors: Raye Miles, Douglas Porter, John Dorrance, Kenneth Courian
-
Patent number: 9944951Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: GrantFiled: May 24, 2011Date of Patent: April 17, 2018Assignees: Board of Regents, The University of Texas System, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
-
Publication number: 20120076851Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: ApplicationFiled: May 24, 2011Publication date: March 29, 2012Inventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
-
Publication number: 20110207217Abstract: Synthesis of a target transcript of a gene is selectively increased in a mammalian cell by contacting the cell with a polynucleotide oligomer of 12-28 bases complementary to a region within a target promoter of the gene under conditions whereby the oligomer selectively increases synthesis of the target transcript.Type: ApplicationFiled: March 30, 2010Publication date: August 25, 2011Inventors: David Reid Corey, Bethany Ann Janowski, David S. Shames, John Dorrance Minna
-
Patent number: 7977468Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: GrantFiled: October 31, 2007Date of Patent: July 12, 2011Assignees: Board of Regents of the University of Texas System, The United States of America as represented by the Department of Health and Human ServicesInventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
-
Patent number: 7902441Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: GrantFiled: May 27, 2003Date of Patent: March 8, 2011Assignees: Board of Regents, The University of Texas, The United States of America as represented by the Department of Health and Human ServicesInventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
-
Publication number: 20090023207Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: ApplicationFiled: October 31, 2007Publication date: January 22, 2009Inventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
-
Patent number: 6979724Abstract: The present invention relates to calcium channel compositions and methods of making and using same. In particular, the invention relates to calcium channel alpha2delta (?2?) subunits and nucleic acid sequences encoding them. These compositions are useful in methods for identifying compounds that modulate the activity of calcium channels and for identifying compounds as therapeutic for disease.Type: GrantFiled: April 5, 2002Date of Patent: December 27, 2005Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, The Board of Regents of the University of Texas SystemInventors: Michael Isaac Lerman, Farida Latif, Ming-Hui Wei, Fuh-Mei Duh, John Dorrance Minna, Yoshitaka Sekido, Boning Gao
-
Publication number: 20040016006Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: ApplicationFiled: May 27, 2003Publication date: January 22, 2004Applicant: U.S. of America, represented by the Secretary, Department of Health and Human Services.Inventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
-
Publication number: 20030044911Abstract: The present invention relates to calcium channel compositions and methods of making and using same. In particular, the invention relates to calcium channel alpha2delta (&agr;2&dgr;) subunits and nucleic acid sequences encoding them. These compositions are useful in methods for identifying compounds that modulate the activity of calcium channels and for identifying compounds as therapeutic for disease.Type: ApplicationFiled: April 5, 2002Publication date: March 6, 2003Inventors: Michael Isaac Lerman, Farida Latif, Ming-Hui Wei, Fuh-Mei Duh, John Dorrance Minna, Yoshitaka Sekido, Boning Gao
-
Publication number: 20020164715Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.Type: ApplicationFiled: July 10, 2001Publication date: November 7, 2002Inventors: Lin Ji, John Dorrance Minna, Jack Roth, Michael Lerman
-
Patent number: 6441156Abstract: The present invention relates to calcium channel compositions and methods of making and using same. In particular, the invention relates to calcium channel alpha2delta (&agr;2&dgr;) subunits and nucleic acid sequences encoding them. These compositions are useful in methods for identifying compounds that modulate the activity of calcium channels and for identifying compounds as therapeutic for disease.Type: GrantFiled: December 22, 1999Date of Patent: August 27, 2002Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Michael Isaac Lerman, Farida Latif, Ming-Hui Wei, Fuh-Mei Duh, John Dorrance Minna, Yoshitaka Sekido, Boning Gao